QIAGEN has Licensed a Novel Algorithm Developed by Novartis for the Selection of siRNA Sequences for Gene Silencing Applications

16-Dec-2003

QIAGEN N.V. announced that it has licensed from Novartis Pharma AG a novel algorithm for the selection of highly functional target sequences for RNA interference applications. More than 3000 randomly designed synthetic siRNA duplexes, against 34 targets were analyzed for functionality. Based on this large data set, an automated siRNA sequence selection algorithm was developed. Extensive evaluation of the new algorithm has demonstrated a significant performance improvement over existing design methods.

Under the terms of this collaboration QIAGEN obtained a fully paid-up license from Novartis for the worldwide use of this prediction algorithm. Financial terms were not disclosed.

"We are very happy that Novartis has made this new resource available to QIAGEN", said Patrick A. Weiss, QIAGEN's Vice President of Gene Silencing and co-inventor of the TOM RNA chemistry. "This powerful tool complements QIAGEN's state of the art synthesis technology, combining biological functionality with high quality siRNA. This means that researchers can focus on their experiments and not on developing functional gene targeting reagents."

Other news from the department business & finance

These products might interest you

Micro-Dx™ CE IVD

Micro-Dx™ CE IVD by Molzym

Fully automated from sample to PCR analysis

Rapid identification of bacteria and fungi without time-consuming cultivation

DNA extraction kits
DNA-free Taq Polymerases and Mastermixes

DNA-free Taq Polymerases and Mastermixes by Molzym

DNA-free reagents for unrivalled sensitivity in molecular biology

Purity that makes the difference

PCR accessories
Greener Alternative Products

Greener Alternative Products by Merck Life Science

Sustainable laboratory products for environmentally conscious research

Over 2,500 ecological alternatives to reduce your laboratory footprint

consumables
CellGenix® Growth Factors and Cytokines

CellGenix® Growth Factors and Cytokines by Sartorius

Recombinant growth factors without animal products

Optimised cell culture for T cells and MSCs in gene therapy

reagents
Recombumin® Elite

Recombumin® Elite by Sartorius

ICHQ7 cGMP-compliant albumin for biotechnological applications

Increase consistency and safety for gene therapies and vaccines

reagents
DNA/RNA Shield™ SafeCollect Collection Kits

DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research

Sample collection devices for simple & safe at-home testing

Best user experience for secure self-collection

kits
Loading...

More news from our other portals

All FT-IR spectrometer manufacturers at a glance